Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 20/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1752280 | 0.95 | F10 (0.54) | F10 | |
| SCHEMBL1752544 | 0.93 | F10 (0.51) | F10 | |
| SCHEMBL1751698 | 0.93 | F10 (0.49) | F10 | |
| SCHEMBL1752413 | 0.92 | F10 (0.53) | F10 | |
| SCHEMBL1751557 | 0.90 | F10 (0.51) | F10 | |
| SCHEMBL1751446 | 0.90 | F10 (0.51) | F10 | |
| SCHEMBL1752281 | 0.90 | F10 (0.52) | F10 | |
| SCHEMBL1752451 | 0.89 | F10 (0.51) | F10 | |
| SCHEMBL1751582 | 0.89 | F10 (0.50) | F10 | |
| SCHEMBL1752265 | 0.89 | F10 (0.52) | F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110160196-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2011-06-30 | — | — | US | claimed |
| EP-2114930-A2 | FACTOR XA INHIBITORS | Millennium Pharmaceuticals, Inc. (US) | 2009-11-11 | — | — | EP | claimed |
| US-20080293704-A1 | FACTOR Xa INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2008-11-27 | — | — | US | claimed |
| WO-2008086226-A2 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-07-17 | — | — | WO | claimed |
| US-20110160196-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2011-06-30 | — | — | US | disclosed |
| US-20110160196-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2011-06-30 | — | — | US | disclosed |
| EP-2114930-A2 | FACTOR XA INHIBITORS | Millennium Pharmaceuticals, Inc. (US) | 2009-11-11 | — | — | EP | disclosed |
| US-20080293704-A1 | FACTOR Xa INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2008-11-27 | — | — | US | disclosed |
| US-20080293704-A1 | FACTOR Xa INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2008-11-27 | — | — | US | disclosed |
| US-20080293704-A1 | FACTOR Xa INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2008-11-27 | — | — | US | disclosed |
| WO-2008086226-A2 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-07-17 | — | — | WO | disclosed |
| WO-2008086226-A2 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293704-A1 | FACTOR Xa INHIBITORS | TFPI, F12, F11 | F10 10/4885 |
| US-20110160196-A1 | FACTOR XA INHIBITORS | TFPI, F12, F11 | F10 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.